Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Rose A. Devasia"'
Autor:
Marion A. Kainer, Rose A. Devasia, Timothy F. Jones, Bryan P. Simmons, Kelley Melton, Susan Chow, Joyce Broyles, Kelly L. Moore, Allen S. Craig, William Schaffner
Publikováno v:
Emerging Infectious Diseases, Vol 13, Iss 7, Pp 1024-1024 (2007)
Linezolid was approved in 2000 for treatment of gram-positive coccal infections. We performed a case-control study during a hospital outbreak of linezolid-resistant enterococci (LRE) infections, comparing cases of LRE infection (cases) with linezolid
Externí odkaz:
https://doaj.org/article/632a5a7be6a34653a7c52798050f539f
Autor:
Rany Octaria, Marion A. Kainer, Yuwei Zhu, Rachel B. Slayton, Rose A. Devasia, Hannah Wolford, Allison Chan, Troy D Moon
Publikováno v:
Emerging Infectious Diseases
Emerging Infectious Diseases, Vol 26, Iss 9, Pp 2046-2053 (2020)
Emerging Infectious Diseases, Vol 26, Iss 9, Pp 2046-2053 (2020)
To identify facilities at risk of receiving patients colonized or infected with multidrug-resistant organisms (MDROs), we developed an interactive web-based interface for visualization of patient-sharing networks among healthcare facilities in Tennes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df5f35d85f78b6ca2c8478f86b173cbe
https://pubmed.ncbi.nlm.nih.gov/32818409
https://pubmed.ncbi.nlm.nih.gov/32818409
Autor:
Lorinda L. Sheeler, Timothy F. Jones, Sandy K. Halford, Jamie Swift, William Schaffner, Rose A. Devasia, Marion A. Kainer
Publikováno v:
Vaccine. 24:1354-1358
Current recommendations have not resulted in routine vaccination of correctional facility inmates for hepatitis B. We investigated two hepatitis B outbreaks. Outbreak 1 involved 4 cases epidemiologically linked to persons who had been in jail. Outbre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1942809e85fbb2c130181b2159acd17e
https://doi.org/10.1016/j.vaccine.2005.09.023
https://doi.org/10.1016/j.vaccine.2005.09.023
Autor:
Charles Alexander, Haijing Li, Rose A. Devasia, Ayumi Shintani, Amondrea Blackman, Fernanda Maruri, Jon Warkentin, Svetlana K. Eden, Timothy R. Sterling, Anne Kaiga, Charles W. Stratton, Yi-Wei Tang
Fluoroquinolone resistance in Mycobacterium tuberculosis can be conferred by mutations in gyrA or gyrB . The prevalence of resistance mutations outside the quinolone resistance-determining region (QRDR) of gyrA or gyrB is unclear, since such regions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2c26a419b33d731daa58de812e7cce9
https://europepmc.org/articles/PMC3421521/
https://europepmc.org/articles/PMC3421521/
Autor:
S. May, Amondrea Blackman, Timothy R. Sterling, Rose A. Devasia, Fernanda Maruri, Charles W. Stratton
Microcolony growth of Mycobacterium tuberculosis on agar proportion susceptibility testing is neither well-defined nor previously reported with fluoroquinolone susceptibility testing. We describe here M. tuberculosis microcolony growth with fluoroqui
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52a529a576b3a734da48311697e01c28
https://europepmc.org/articles/PMC3981548/
https://europepmc.org/articles/PMC3981548/
Autor:
Ed Mitchel, Rose A. Devasia, Tebeb Gebretsadik, Marie R. Griffin, Timothy R. Sterling, Fernanda Maruri, Ayumi Shintani, Amondrea Blackman, Jon Warkentin, Carolyn May, Teresa Smith, Nancy Hooper
Publikováno v:
American journal of respiratory and critical care medicine. 180(4)
Rationale: Fluoroquinolones are the most commonly prescribed antibiotic class in the United States. They have the potential to become first-line antituberculosis therapy, but the effect of fluoroquinolone use on fluoroquinolone resistance in Mycobact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ad7b622cd9cad05922f969851b4f3e8
https://pubmed.ncbi.nlm.nih.gov/19661251
https://pubmed.ncbi.nlm.nih.gov/19661251
Autor:
Rose A. Devasia, Jon Warkentin, Charles W. Stratton, Timothy R. Sterling, H Price, Amondrea Blackman, S. May, Fernanda Maruri, Teresa Smith
Publikováno v:
B48. DIAGNOSIS OF MYCOBACTERIAL DISEASE.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40ea34ab8e03598dbe860bd5bea6f08e
https://doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a3198
https://doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a3198
Autor:
Nancy Hooper, Teresa Smith, Carolyn May, Ayumi Shintani, Amondrea Blackman, Timothy R. Sterling, Charles W. Stratton, Svetlana K. Eden, Fernanda Maruri, Rose A. Devasia
Publikováno v:
The Journal of antimicrobial chemotherapy. 63(6)
The aim of this study was to assess the sensitivity, specificity and time to results of mycobacterial growth indicator tube (MGIT) 960, microscopic observation drug susceptibility (MODS) assay and nitrate reductase assay (NRA) compared with the gold
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fd75bbdfdf0d9b74d9be19da12ad146
https://pubmed.ncbi.nlm.nih.gov/19329799
https://pubmed.ncbi.nlm.nih.gov/19329799
Publikováno v:
The American journal of the medical sciences. 337(3)
Background Erythromycin has traditionally been the choice for prophylaxis and treatment of pertussis, but recently azithromycin has been recommended as another first-line agent. We evaluated treatment adherence between exposed persons giving erythrom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad1f3e88a79d1eb29f73eef5cc565d76
https://pubmed.ncbi.nlm.nih.gov/19301451
https://pubmed.ncbi.nlm.nih.gov/19301451
Autor:
Kelly L. Moore, Bryan P. Simmons, Rose A. Devasia, Allen S. Craig, Joyce E. Broyles, William Schaffner, Kelley Melton, Timothy F. Jones, Susan Chow, Marion A. Kainer
Publikováno v:
Emerging Infectious Diseases
Emerging Infectious Diseases, Vol 13, Iss 7, Pp 1024-1024 (2007)
Emerging Infectious Diseases, Vol 13, Iss 7, Pp 1024-1024 (2007)
These bacteria have emerged as a hospital problem that appears to be caused by both linezolid exposure and patient-to-patient transmission.
Linezolid was approved in 2000 for treatment of gram-positive coccal infections. We performed a case-cont
Linezolid was approved in 2000 for treatment of gram-positive coccal infections. We performed a case-cont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaff1fee3d9bf903f9d690584184a0a5
https://pubmed.ncbi.nlm.nih.gov/18214174
https://pubmed.ncbi.nlm.nih.gov/18214174